Work

Abstract CT030: A phase 1b/2a, open-label, multicenter, randomized, dose escalation study evaluating the safety, tolerability and efficacy of RZ-001 in combination with valganciclovir (VGCV) and atezolizumab/bevacizumab in subjects with hepatocellular carcinoma

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct030

Authors: Yong Han Paik, Yoon Jun Kim, Won Young Tak, Do Young Kim, Jeong Won Jang, Hyun Woong Lee, Young Sun Lee, Won Son, Ki Tae Yoon, Seong-Wook Lee, Sung Woo Hong, Eunjee Jeon

Institutions: Samsung Medical Center, Severance Hospital, Seoul National University Hospital, Yonsei University Health System, Kyungpook National University Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Gangnam Severance Hospital, Korea University Guro Hospital, Kangbuk Samsung Hospital, Pusan National University Yangsan Hospital

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154754990

Cites:

Cited by:

Related to: